

Supplementary Materials: The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer

Claire L. Tonry, Emma Leacy, Cinzia Raso, Stephen P. Finn, John Armstrong and Stephen R. Pennington

Table S1. Tumor Staging in Prostate Cancer [1] ¹.

Primary Tumor (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Clinically inapparent tumor not palpable or visible by imaging
T1a	Tumor incidental histologic finding in ≤5% of tissue resected
T1b	Tumor incidental histologic finding in >5% of tissue resected
T1c	Tumor identified by needle biopsy (because of elevated prostate specific antigen [PSA] level)
T2	Tumor confined within prostate; tumors found in 1 or both lobes by needle biopsy but not palpable or reliably visible by imaging
T2a	Tumor involves one-half of 1 lobe or less
T2b	Tumor involves more than one-half of 1 lobe but not both lobes
T2c	Tumor involves both lobes
T3	Tumor extends through the prostatic capsule; invasion into the prostatic apex, or the prostatic capsule is classified not as T3 but as T2
T3a	Extracapsular extension (unilateral or bilateral)
T3b	Tumor invading seminal vesicle(s)
T4	Tumor fixed or invades adjacent structures other than seminal vesicles (e.g., bladder, levator muscles, and/or pelvic wall)
Pathologic (pT) *	
pT2	Organ confined
pT2a	Unilateral, involving one-half of 1 lobe or less
pT2b	Unilateral, involving more than one-half of 1 lobe but not both lobes
pT2c	Bilateral disease
pT3	Extraprostatic extension
pT3a	Extraprostatic extension or microscopic invasion of the bladder neck
pT3b	Seminal vesicle invasion
pT4	Invasion of the bladder and rectum
* Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease)	
Regional lymph nodes (N)	
<i>Clinical</i>	
NX	Regional lymph nodes were not assessed
N0	No regional lymph node metastasis
N1	Metastasis in regional lymph node(s)
<i>Pathologic</i>	
PNX	Regional nodes not sampled
pN0	No positive regional nodes
pN1	Metastases in regional nodes(s)
Distant metastasis (M) *	
M0	No distant metastasis

M1	Distant metastasis
M1a	Nonregional lymph nodes(s)
M1b	Bone(s)
M1c	Other site(s) with or without bone disease

¹ Table adapted from National Comprehensive Cancer Network.

Reference

1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.1.2015. Available online: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed on 30 December 2015).